CTOs on the Move

AbbVie Canada

www.abbvie.ca

 
We`re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people`s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company. Our ~30,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We come up with new approaches to addressing today`s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We`re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients` ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.abbvie.ca
  • 8401 Trans-Canada Highway
    Saint-Laurent, QC CAN H4S 1Z1
  • Phone: 514.906.9700

Executives

Name Title Contact Details

Similar Companies

Ohm Laboratories

Ohm Laboratories is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centric Health Resources

Centric Health Resources is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Long Term Care Pharmacy Alliance

Long Term Care Pharmacy Alliance is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GreenwichBiosciences

Greenwich Biosciences is the leader in researching cannabinoid medicines for rare epilepsies like Dravet Syndrome, LGS, TSC, and others.

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.